The MAD7 nuclease: made for discovery.

Not all nucleases are created equal

There is a wide variety of naturally occurring and engineered CRISPR nucleases. This diversity can be useful when choosing the right nuclease for editing a specific organism or accessing different CRISPR applications. CRISPR nucleases vary in size, corresponding gRNA structures, PAM requirements, and other characteristics. Selecting the nuclease that fits your research needs is an important step for a successful genome engineering project.

Democratizing genome engineering

Inspired by the biological diversity found on the island of Madagascar, the MADzyme nucleases have improved features over commonly used Cas9 nucleases, such as different PAM recognition sequences and cutting efficiencies, fewer off-target effects, reduced size and differing enzyme kinetics. 

We developed and publicly released the MAD7 nuclease, the first of the MADzyme nucleases, to promote widespread adoption of CRISPR tools in academic and commercial settings. The MAD7 nuclease has already been shown to be effective in microbial, plant, fish, and mammalian (including human) systems. Go ahead and try it, the MAD7 nuclease is royalty-free for both academic and commercial research and development use.

MAD7 nuclease structural model
Separator

The MAD7 nuclease in mammalian cells

In addition to robust performance in prokaryotic and eukaryotic microbial systems, the MAD7 nuclease has demonstrated editing activity in mammalian cells.
For example, initial experiments in HEK293T cells show that the MAD7 nuclease can be expressed as an active protein in mammalian cells, and when combined with synthetic guide RNAs, can edit different genes at multiple loci.
Separator

Is the MAD7 nuclease really free?

For most academic and commercial R&D, access to the MAD7 nuclease is free. Inscripta provides the DNA sequence of the E. coli or human codon-optimized MAD7 nuclease without reach-through royalty rights for all but a limited number of uses. Royalties are ONLY attached to the use of the MAD7 nuclease in commercial manufacturing processes or in products that physically contain or encode for the MAD7 nuclease. A free, non-exclusive license is provided when the sequence is downloaded, and if requested, Inscripta can provide a hard copy license for the free uses of the MAD7 nuclease in R&D.
Separator

Commercial MADzyme licenses 

Inscripta believes that CRISPR technology is transformative and can offer technical solutions to many of today’s most challenging biological questions. Based on this philosophy, Inscripta provides end users widespread access to the MAD7 CRISPR technology rather than tying them up in exclusive relationships. Our commercial licensing approach for the MAD7 nuclease and other MADzyme nucleases is designed to promote both academic and commercial adoption of our nucleases for product development and commercialization.
For commercial uses that require a license, Inscripta makes the MAD7 nuclease – as well as certain other MADzyme nucleases – available through our non-exclusive, enabling MADzyme licensing program. These licenses are available on a non-exclusive basis on commercially reasonable terms. For more information on the commercial licensing of the MAD7 nuclease or other MADzymes, please contact us.
Separator

How well does it work?

If you are wondering how well does the MAD7 nuclease work?”, we have performed extensive characterization and testing of the MAD7 nuclease in both microbial and mammalian systems. Here you can find the technical data on the editing efficiency and performance in yeast and E. coli, the structure of the MAD7 nuclease and preferred PAM sites, expression recommendations, and how to get started using the MAD7 nuclease in your lab.

Separator

The MAD7 nuclease in the news

A key part of Inscripta’s mission is making genome engineering more accessible. Since the MAD7 nuclease sequence is publicly available and free to use in most cases, labs around the world are using it for different applications. Read about the recent publications, novel applications, and other MAD7 nuclease news.